Medtech Orthopaedics operating margin measures segment operating income as a percentage of Orthopaedics net sales.
Stryker reported a 34.0% Orthopaedics operating margin in the second quarter of 2026, up from 33.1% a year earlier.
Volume and lower operating expenses supported margin
Stryker's margin bridge showed favorable contributions from volume, R&D expense, and SG&A expense, partly offset by manufacturing and supply-chain costs.
The margin therefore captures the segment's operating conversion rather than any one implant category.
Product-family growth can diverge inside the segment
Knees, Hips, Trauma and Extremities, and Ortho Tech all posted different constant-currency growth rates during the quarter.
Use the margin with Knees constant-currency sales growth and Trauma and Extremities constant-currency sales growth.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsSegment operating conversion2 of 2 bridge concepts supportedContinue through this bridge:MedSurg & Neurotechnology Margin
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare Orthopaedics margins
Compare Orthopaedics operating conversion while preserving product-family mix, volume, R&D, SG&A, and supply-chain effects.
Explore more topics in the Financial Research Encyclopedia.